Connect with us

Covid

Covaxin, Covishield or Sputnik V: Which is better?

Published

on

Covaxin, Covishield or Sputnik V: Which is better?

At present, India has three different Covid-19 vaccines – Covaxin, Covishield  and Sputnik V. But do you know which one is better? Well, fret not! Read this piece.

Sputnik V: With an efficacy of 92 per cent, the Sputnik V has been manufactured by Gamalaya Institute, Moscow and it is a vector vaccine based on an adenovirus. Also, two slightly different versions of the vaccine are administered 21 days apart.

Covaxin: Manufactured by Bharat Biotech, the covaxin is an inactivated vaccine which contains the virus and this triggers an immune response but does not make the person ill. The efficacy rate is 81 per cent and the duration between two doses is 28 days.

Covishield: Based on the viral vector platform and is made from a weakened version of a coomon cold virus from chimpanzees, the Covishield is produced by the Serum Institute of India. It has an efficacy of 70 per cent and the two doses are administered by 12 weeks apart.

Covid

Covaxin protects recipients from severe Covid-19: Researchers

Published

on

By

Covaxin protects recipients from severe Covid-19: Researchers

According to the researchers, India’s Covaxin activates key memory components of the human immune system that can continue to protect recipients from severe Covid-19 even after the vaccine-generated anti-viral antibodies have waned.

“We see amazingly robust immune memory responses very similar to those caused by the natural infection,” said Nimesh Gupta, a scientist at the National Institute of Immunology (NII), New Delhi, who led the study.

“These memory responses will outlast and confer protection even the concentrations of the initial antibodies deplete over months,” Gupta said.

Continue Reading

Covid

Covid-19 in India: 8,488 new Covid cases in last 24 hours, lowest in 538 days

Published

on

By

On Monday, India reported 8,488 new cases over the previous 24 hours, 19.1% lower than Sunday’s statistics. This was the lowest in 538 days.

With this, country’s cumulative caseload to 3,45,18,901. The number of active cases now stands at 1,18,443 — the lowest in 534 days.

As per the Health Ministry data, as many as 12,510 recoveries were recorded on Monday over the previous 24 hours while the number of deaths stood at 249, taking the total toll to 4,65,911.

The top five states that registered the maximum cases were Kerala with 5,080 cases, followed by Tamil Nadu with 756 cases, West Bengal with 727 cases, Maharashtra with 298 cases, and Karnataka with 247 cases. As much as 83.75% of the new cases were reported from these five states.

Continue Reading

Covid

Covaxin 77.8% effective against Covid-19

Published

on

By

Covaxin 77.8% effective against Covid-19

Medical journal Lancet has now stated that the made-in-India vaccine is 77.8 per cent effective against symptomatic Covid, as demonstrated by the phase 3 data. This came out after the World Health Organisation (WHO) approved Bharat Biotech’s Covaxin for emergency use.

The efficacy data demonstrated 70.8 per cent protection against all variants of the SARS-CoV-2 virus.

As per the phase 3 data, Covaxin was found to be 65.2 per cent effective against the Delta variant, 93.4 per cent effective against severe symptomatic Covid and 63.6 per cent effective against asymptomatic Covid.

Dr. Krishna Ella, CMD of Bharat Biotech said, “The peer-review of Covaxin phase III clinical trial data in The Lancet, an authoritative voice in global medicine, validates our commitment to data transparency and meeting the stringent peer-review standards of world-leading medical journals. This accomplishment reflects the undeterred commitment by my team members at Bharat Biotech, our public partners, Indian Council of Medical Research, National Institute of Virology, and the trust imposed by our trial participants who made this happen.”

Continue Reading

Trending